Fostamatinib - Rigel Pharmaceuticals
Alternative Names: FosD; Fostamatinib disodium; Fostamatinib disodium hexahydrate; Fostamatinib sodium; R 985788; R-406/788; R-788; R-935/788; R788 sodium; R935788 sodium; Tamatinib fosdium; TAVALISSE; Tavalisse; TAVLESSELatest Information Update: 27 May 2025
At a glance
- Originator Rigel Pharmaceuticals
- Developer AstraZeneca; Duke University Medical Center; Grifols; JW Pharmaceutical; Kissei Pharmaceutical; Knight Therapeutics; National Heart, Lung and Blood Institute; Rigel Pharmaceuticals; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Vanderbilt University Medical Center
- Class Anti-inflammatories; Antianaemics; Antihyperglycaemics; Antineoplastics; Antirheumatics; Oxazines; Phosphoric acid esters; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action Syk kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Idiopathic thrombocytopenic purpura
- Preregistration COVID 2019 infections
- Phase III Autoimmune haemolytic anaemia
- Phase II/III COVID-19 pneumonia
- No development reported Graft-versus-host disease; Ovarian cancer; Waldenstrom's macroglobulinaemia
- Discontinued Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; IgA nephropathy; Rheumatoid arthritis; Solid tumours; Systemic lupus erythematosus; T-cell lymphoma; Type 1 diabetes mellitus
Most Recent Events
- 31 Mar 2025 Preregistration for Idiopathic thrombocytopenic purpura (Treatment-experienced) in Argentina (PO)
- 27 Mar 2025 Rigel Pharmaceuticals resolves patent litigation against Annora Pharma over ANDA submission in US
- 21 Jan 2025 Registered for Idiopathic thrombocytopenic purpura (Treatment-experienced, In adults) in South Korea (PO)